Verastem Q3 adjusted loss widens on increased R&D expenses

By Reuters News


Overview

  • US biopharma firm's Q3 net product revenue more than doubled yr/yr to $24 mln

  • Adjusted loss per share for Q3 missed analyst expectations

  • Company completed $250 mln public offering in October to fund clinical development


Outlook

  • Verastem expects FDA decision on AVMAPKI FAKZYNJA CO-PACK Blister Pack by Feb 7, 2027

  • Company plans to open Phase 3 TARGET-D 301 trial in 1L mPDAC by year-end 2026

  • Verastem expects cash runway to extend into 1H 2028, funding pivotal Phase 3 studies


Result Drivers

  • STEADY PRODUCT DEMAND - Co said AVMAPKI FAKZYNJA CO-PACK revenue was driven by strong refill growth, though offset by fewer new patient starts due to seasonal headwinds, commercial team changes, and evolving off-label use patterns

  • INCREASED R&D SPENDING - Co attributed higher research and development expenses to increased costs for investigator fees, manufacturing, contract research organizations, and personnel, including stock-based compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted Loss Per Share

Miss

$0.72

$0.46 (10 Analysts)

Q3 Net Loss

$74.72 mln

Q3 Income from Operations

-$75.22 mln

Q3 Operating Expenses

$99.24 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Verastem Inc is $18.00, about 82.7% above its November 4 closing price of $9.85


Reuters Recommended Reads

  • Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall

  • Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall

  • Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.